Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Net Cash Flow (2020 - 2025)

GeneDx Holdings has reported Net Cash Flow over the past 6 years, most recently at $9.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $9.0 million for Q4 2025, down 66.94% from a year ago — trailing twelve months through Dec 2025 was $19.8 million (up 236.78% YoY), and the annual figure for FY2025 was $19.8 million, up 236.78%.
  • Net Cash Flow for Q4 2025 was $9.0 million at GeneDx Holdings, down from $21.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for WGSWW hit a ceiling of $424.8 million in Q3 2021 and a floor of -$93.3 million in Q3 2022.
  • Median Net Cash Flow over the past 5 years was -$21.2 million (2022), compared with a mean of -$648550.0.
  • Peak annual rise in Net Cash Flow hit 37167.97% in 2021, while the deepest fall reached 5645.63% in 2021.
  • GeneDx Holdings' Net Cash Flow stood at -$60.7 million in 2021, then dropped by 11.07% to -$67.4 million in 2022, then surged by 118.36% to $12.4 million in 2023, then skyrocketed by 120.67% to $27.3 million in 2024, then plummeted by 66.94% to $9.0 million in 2025.
  • The last three reported values for Net Cash Flow were $9.0 million (Q4 2025), $21.8 million (Q3 2025), and -$25.6 million (Q2 2025) per Business Quant data.